10-K: Organogenesis Holdings Inc. Reports 2024 Annual Results, Outlines Strategic Growth Initiatives

Organogenesis Holdings Inc. files its 10-K report for the fiscal year ended December 31, 2024, detailing its financial performance and strategic plans for growth in the regenerative medicine and tissue innovation markets.

Summary

• Organogenesis Holdings Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company focuses on regenerative medicine and tissue innovations, developing and selling products for advanced wound care and surgical/sports medicine markets.
• Organogenesis is pursuing strategic growth initiatives, including operating and commercial activities, clinical development programs, working capital management, capital expenditures, and debt repayment.
• In November 2024, the company completed a Series A Convertible Preferred Stock financing, raising $130 million in gross proceeds.
• Approximately $25.5 million from the financing was used to repurchase 7,921,731 shares of Class A common stock.
• The company expects to submit a biologics license application (BLA) for ReNu in symptomatic knee osteoarthritis (OA) in the second half of 2025.
• Organogenesis intends to commence manufacturing of Dermagraft, Apligraf, and PuraPly at its new biomanufacturing facility in Smithfield, Rhode Island, expected to begin in 2027.
• The company is obligated to complete the build out of the Smithfield Facility within thirty-six (36) months of the lease signing.
• The company has a right to terminate the lease for a payment to Davis of $1.3 million, if it has not secured certain anticipated state and local tax incentives by March 31, 2025.
• The company reported results consistent with the predefined requirements for study success: statistically significant reduction in knee pain (p=0.0177) and statistically significant maintenance of function (p<0.0001) at six months.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has secured significant funding and has promising clinical trial results, there are also concerns about fluctuating operating results, regulatory challenges, and increasing competition.

Positives

• The company successfully raised capital through a Series A Convertible Preferred Stock financing.
• Clinical trials for ReNu in knee OA have shown promising results.
• The new biomanufacturing facility in Smithfield, Rhode Island, is expected to lead to long-term cost savings.
• The company has remediated a previously reported material weakness in its internal control over financial reporting.

Negatives

• Manufacturing and sales of Dermagraft remain suspended, although a transition to the new facility is planned.
• The company incurred non-cash impairment and write down charges during 2024 which adversely affected its fiscal year 2024 operating results.
• The company may be required to incur additional future impairment and write down charges, which could adversely affect its operating results.

Risks

• The company faces significant competition in the regenerative medicine market.
• Reimbursement rates and coverage for the company's products by government and private payers are subject to change.
• The company's operating results may fluctuate significantly due to various factors, many of which are outside of its control.
• The company's success depends on convincing physicians that its products are safe and effective alternatives to existing treatments.
• The company is subject to various governmental regulations relating to the labeling, marketing, and sale of its products.
• The company may be required to record a significant charge to earnings if its goodwill and other amortizable intangible assets, or other assets become impaired.
• The company's ability to use its net operating loss carryforwards may be subject to certain limitations.

Future Outlook

The company plans to continue to leverage its comprehensive product portfolio and relationships with key constituents to deepen its presence in the Advanced Wound Care market and accelerate penetration into the Surgical & Sports Medicine market. They also plan to expand sales outside of the United States and launch new products in the coming years.

Management Comments

• Management uses Adjusted EBITDA to evaluate operating performance and trends and make planning decisions.
• Management believes Adjusted EBITDA helps identify underlying trends in the business that could otherwise be masked by the effect of the items that we exclude.

Industry Context

The company operates in the regenerative medicine and tissue innovation markets, which are driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease. The advanced wound care market is estimated at approximately $20 billion as of 2021, and the total addressable OA market is estimated at approximately $7 billion as of 2023.

Comparison to Industry Standards

• Apligraf is the leading skin substitute product for the treatment of VLUs.
• Dermagraft has demonstrated superior clinical efficacy and value as compared to competitive wound care products and conventional therapy.
• The company believes that it is one of the few regenerative medicine companies offering PMA approved and 510(k) cleared products in addition to its 361 HCT/Ps.

Legal Proceedings

• On January 22, 2025, the Company was served with a complaint captioned United States of America, State of Texas, ex rel. John Doe vs. Organogenesis Holdings, Inc., which was filed in the United States District Court for the Southern District of Texas.
• The complaint is being brought by an employee the Company terminated.
• The United States and the State of Texas each declined to intervene in the case in September 2024.
• The complaint alleges claims pursuant to the United States False Claims Act and the Texas State Medicaid Fraud Prevention Act, seeking unquantified damages as well as fines, attorneys fees and other costs.
• The Company believes the claims are without merit and intends to vigorously contest them.

Related Party Transactions

• The company leases buildings in Canton from entities controlled by certain stockholders.
• Approximately $25.5 million from the financing was used to repurchase 7,921,731 shares of Class A common stock from certain existing stockholders of the Company, including certain of its directors and their affiliates.

Stakeholder Impact

• The company's performance and strategic initiatives will impact shareholders, employees, customers, suppliers, and creditors.
• The success of the company's products and clinical trials will affect patient outcomes and healthcare costs.

Next Steps

• The company expects to submit a biologics license application (BLA) for ReNu in symptomatic knee osteoarthritis (OA) in the second half of 2025.
• Organogenesis intends to commence manufacturing of Dermagraft, Apligraf, and PuraPly at its new biomanufacturing facility in Smithfield, Rhode Island, expected to begin in 2027.

Key Dates